Nucleix Ltd.
10
2
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
10.0%
1 terminated/withdrawn out of 10 trials
83.3%
-3.2% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Bladder EpiCheck European Haematuria Study
Role: lead
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
Role: lead
Lung EpiCheck Biomarkers Development Study
Role: lead
Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
Role: lead
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
Role: lead
Characterization of Methylation Patterns in Hepatocellular Carcinoma
Role: lead
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma
Role: lead
Characterization of Methylation Patterns in Lung Cancer
Role: lead
Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma
Role: lead
Genetic Testing in Upper Tract Urothelial Carcinoma (UTUC): the Epicheck Study
Role: collaborator
All 10 trials loaded